Gallium-68-DOTA-minigastrin

N/A

Report date: 2025/11/20 13:28:13

NME

Base Information

Drug NameGallium-68-DOTA-minigastrin

Drug Alias Name68Ga-labelled [DOTA0,DGlu1,desGlu2-6,(N-Me)Nle11,1-Nal13]minigastrin (68Ga-DOTA-MGS5)68Ga-labelled minigastrin analogue68Ga-DOTA-MGS5

ClassificationRadiation-emitting products > Nuclides > Gallium > 68GaRadiation-emitting products > Radionuclide Drug ConjugatesRadiation-emitting products > Radioactive diagnostic agent +[4]

Mechanisms of ActionPositron-emission tomography enhancers

TargetsNot applicable

Therapy Area/IndicationsNeuroendocrine Tumors

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryAustria

CombinationsNo

Global Highest StatusPhase 2 Clinical

Highest Status in ChinaN/A

Originator CompaniesNovartis Pharma Ag

China Registration ClassN/A

Develop Information

Active CompaniesMedical University Of Innsbruck Novartis Pharma Ag

Inactive CompaniesN/A

Active IndicationsNeuroendocrine Tumors

Inactive IndicationsN/A

Other Information

ATC CodeN/A